CRISPR-Cas9 gene therapy for monogenic blood disorders

AIMS: We aim to develop a CRISPR-Cas-based gene therapy platform for monogenic blood disorders.

BACKGROUND: The novel CRISPR-Cas system can be used to cure various genetic blood diseases by correcting the causative mutation in harvested patient stem cells, that are then infused back to the patient.

WORKPLAN: We have developed a modified CRISPR system that utilizes an engineered Cas9 that is more efficient in inducing HR (homologous recombination) -mediated precision genome editing than wild-type Cas9. As HR-mediated mutation correction happens exclusively in the synthesis (S) phase of the cell cycle, the platform also uses an inhibitor that allows Cas9 only to be active in the S phase, thus increasing safety of the technology. In addition, we have bound the repair template to Cas9, and will transiently inhibit p53 during genome editing.

SIGNIFICANCE: If successful, the method can treat a wide variety of diseases and mutations. It can also be used for cancer immunotherapy and other applications that benefit from clinical immune cell engineering.

 

Les mer om prosjektet

Samarbeid

  • Samarbeid med Oslo Universitetssykkehus, Karolinska Institutet og Karolinska Institutet
  • UiO er forskningsansvarlig

Prosjektbeskrivelse med vedlegg

Disse dokumentene er kun synlige for prosjektleder, enhetens leder og forskningsadministrasjon.

TSD

  • Nei

Biobank

Godkjenninger

REK - Ja

Dokument ikke lastet opp

Prosjektleder / prosjektansvarlig ved UiO

Emma Haapaniemi

Ansvarlig enhet

Norsk Senter for Molekylærmedisin

Forskere

Prosjekttype

  • Forskerprosjekt

Helsefaglig forskning

  • Ja

Personopplysninger

  • Nei

Tidsperiode

  • Start: januar 2019
  • Slutt: januar 2024